For decades, radiation oncology advanced incrementally, improving precision through software and delivery techniques ...

Millions of men are already blocking time on their calendars for college basketball's biggest month. ProCure Proton Therapy Center, located right here in Somerset, is asking them to add one more item ...

U.S. Particle Therapy Market is predicted to increase from 0.52 billion in 2025 to 1.04 billion by 2035 due to increasing cancer cases in the countryAustin, March 25, 2026 (GLOBE NEWSWIRE) -- ...

Medicare typically covers proton therapy when sparing surrounding tissue is not possible with traditional radiation therapy and when this approach would benefit the individual. Medicare Part A covers ...

Proton beam therapy induced survival outcomes that were equal to or better than photon radiotherapy, and may represent a viable treatment option for some patients with pediatric neuroblastoma.

From left, Drew Crandall, director of community engagement for Danbury Proton; Danbury Mayor Roberto Alves; and Stephen Courtney, managing director ...

Texas Center for Proton Therapy has been serving cancer patients in Dallas-Fort Worth and beyond for nearly a decade. The 63,000-square-foot facility located in Irving is one of approximately 45 ...

Phase 2 study shows proton therapy kept 79.1% of patients progression free at five years and limited severe side effects compared with older radiation data. Investigators at Mass General Brigham ...

Annemarie Shepherd, MD, medical director of Fred Hutch Cancer Center – Proton Therapy, has a special interest in thymic cancers, a type of thoracic cancer. Thoracic cancers develops in the chest, or ...

Fred Hutch Cancer Center is excited to introduce Annemarie Shepherd, MD, the new medical director for Fred Hutch Cancer Center - Proton Therapy. Shepherd will start on September 1 and has extensive ...

For decades, radiation oncology advanced incrementally, improving precision through software and delivery techniques while ...

Landmark Proton Therapy Data Changes The Conversation LIXTE Saw It Coming. A landmark Phase III trial published in The Lancet demonstrated a five-year overall survival rate of 90.9% for oropharyngeal ...